Reverse genetics systems

Abstract

The invention provides various reverse genetics systems for producing segmented RNA viruses, wherein the systems do not require bacteria for propagation of all of their expression constructs.

Claims

1. A non-bacterial DNA construct comprising a promoter and coding sequences for expressing at least two different genome segments of a segmented RNA virus, wherein the construct lacks both a bacterial origin of replication and a bacterial selection marker, wherein the at least two segments are selected from the group of segments consisting of PB2, PB1, PA, HA, NP, NA, M and NS, wherein the construct is linear, and, wherein the promoter is operatively linked for transcription in an eukaryotic host cell, wherein the eukaryotic host cell is a mammalian cell or avian cell.

2. A eukaryotic host cell comprising the non-bacterial construct of claim 1.

3. A method for producing a segmented RNA virus, comprising a step of culturing a host cell of claim 2 such that expression of the RNA virus segments occurs to produce the virus.

4. The host cell of claim 2, wherein the cell is a MDCK cell.

5. The non-bacterial DNA construct of claim 1, wherein the coding sequences are for influenza virus A or B genome segments PB2, PB1, PA, NP, and NS.

6. A method for producing a segmented RNA virus, comprising a) transfecting a host cell with the construct of claim 1, and b) culturing the host cell such that expression of the RNA virus segments occurs to produce the virus; wherein the host cell is a mammalian or avian host cell.

7. A non-bacterial DNA construct comprising a promoter and coding sequences for expressing all eight genome segments of an influenza A or B virus, wherein the construct lacks both a bacterial origin of replication and a bacterial selection marker, wherein the promoter is operatively linked for transcription in an eukaryotic host cell, wherein the eukaryotic host cell is a mammalian cell or avian cell, and wherein the construct is linear.

8. A eukaryotic host cell comprising the non-bacterial construct of claim 7.

9. A method for producing a segmented RNA virus, comprising a step of culturing a host cell of claim 8 such that expression of the RNA virus segments occurs to produce the virus.

10. The host cell of claim 8, wherein the cell is a MDCK cell.

Description

(1) It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention.

REFERENCES

(2) [1] Racaniello & Baltimore (1981) Science 214:916-919.

(3) [2] Kaplan et al. (1985) Proc Natl Acad Sci USA 82: 8424-8428.

(4) [3] Fodor et al. (1999) J. Virol 73(11):9679-9682.

(5) [4] Hoffmann et al. (2002) Proc Natl Acad Sci USA 99:11411-6.

(6) [5] Kobayashi et al. (2007) Cell Host Microbe 19;1(2):147-57.

(7) [6] WO2009/000891.

(8) [7] Kodumal et al. (2004) Proc Natl Acad Sci USA. 101(44):15573-8.

(9) [8] Gibson et al. (2008) Science 319(5867):1215-20.

(10) [9] Yount et al. (2002) J Virol 76:11065-78.

(11) [10] Wang & Kushner (1991) Gene 100:195-9.

(12) [11] Shi & Biek (1995) Gene 164:55-8.

(13) [12] WO2006/067211.

(14) [13] WO01/83794.

(15) [14] WO2007/002008.

(16) [15] WO2007/124327.

(17) [16] U.S. Pat. No. 6,468,544.

(18) [17] WO99/64068.

(19) [18] Efferson et al. (2006) J Virol. 80(1):383-94.

(20) [19] Kistner et al. (1998) Vaccine 16:960-8.

(21) [20] Kistner et al. (1999) Dev Biol Stand 98:101-110.

(22) [21] Bruhl et al. (2000) Vaccine 19:1149-58.

(23) [22] WO2006/108846.

(24) [23] Pau et al. (2001) Vaccine 19:2716-21.

(25) [24] http://www.atcc.org/

(26) [25] http://locus.umdnj.edu/

(27) [26]WO97/37000.

(28) [27] Brands et al. (1999)Dev Biol Stand 98:93-100.

(29) [28] Halperin et al. (2002) Vaccine 20:1240-7.

(30) [29] EP-A-1260581 (WO01/64846). [30] WO2006/071563.

(31) [31] WO2005/113758.

(32) [32] Vaccines. (eds. Plotkins & Orenstein). 4th edition, 2004, ISBN: 0-7216-9688-0.

(33) [33] WO02/28422.

(34) [34] WO02/067983.

(35) [35] WO02/074336.

(36) [36] WO01/21151.

(37) [37] WO02/097072.

(38) [38] WO2005/113756.

(39) [39] Huckriede et al. (2003) Methods Enzymol 373:74-91.

(40) [40] Treanor et al. (1996) J Infect Dis 173:1467-70.

(41) [41] Keitel et al. (1996) Clin Diagn Lab Immunol 3:507-10.

(42) [42] Herlocher et al. (2004) J Infect Dis 190(9):1627-30.

(43) [43] Le et al. (2005) Nature 437(7062):1108.

(44) [44] WO2008/068631.

(45) [45] WO97/37001.

(46) [46] EP-B-0870508.

(47) [47] U.S. Pat. No. 5,948,410.

(48) [48] WO2007/052163.

(49) [49] Gennaro (2000) Remington: The Science and Practice of Pharmacy. 20th ed, ISBN: 0683306472.

(50) [50] Banzhoff (2000) Immunology Letters 71:91-96.

(51) [51] Nony et al. (2001) Vaccine 27:3645-51.

(52) [52] WO90/14837.

(53) [53] Podda & Del Giudice (2003) Expert Rev Vaccines 2:197-203.

(54) [54] Podda (2001) Vaccine 19: 2673-2680.

(55) [55] Vaccine Design: The Subunit and Adjuvant Approach (eds. Powell & Newman) Plenum Press 1995 (ISBN 0-306-44867-X).

(56) [56] Vaccine Adjuvants: Preparation Methods and Research Protocols (Volume 42 of Methods in Molecular Medicine series). ISBN: 1-59259-083-7. Ed. O'Hagan.

(57) [57] WO2008/043774.

(58) [58] Allison & Byars (1992) Res Immunol 143:519-25.

(59) [59] Hariharan et al. (1995) Cancer Res 55:3486-9.

(60) [60] US-2007/0014805.

(61) [61] US-2007/0191314.

(62) [62] Suli et al. (2004) Vaccine 22(25-26):3464-9.

(63) [63] WO95/11700.

(64) [64] WO2005/097181.

(65) [65] Greenbaum et al. (2004) Vaccine 22:2566-77.

(66) [66] Zurbriggen et al. (2003) Expert Rev Vaccines 2:295-304.

(67) [67] Piascik (2003) J Am Pharm Assoc (Wash. D.C.). 43:728-30.